Rock Creek Pharmaceuticals Inc. (RCPI) 0.28 $RCPI
Bankruptcy Filing Fallout Continues For NII Holdings
at The Street - Fri Sep 19, 4:16PM CDT
Corinthian Colleges Inc (NASDAQ:COCO), Rock Creek Pharmaceuticals Inc (NASDAQ:RCPI) and dELiA*s, Inc. (NASDAQ
LIA) are today's top-gaining stocks. The losers are NII Holdings Inc (NASDAQ:NIHD), T...
Rite Aid Plunges As Full-Year Outlook Dims
at The Street - Thu Sep 18, 12:04PM CDT
KiOR Inc (NASDAQ:KIOR), NII Holdings Inc (NASDAQ:NIHD) and Rock Creek Pharmaceuticals Inc (NASDAQ:RCPI) are this Thursday's top-gaining billionaire investment picks. On the losing end are Repros ...
Rock Creek Pharmaceuticals Receives New Dietary Ingredient Notification (NDIN) Response
PR Newswire - Fri Sep 12, 7:30AM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today it has received a written response from the U.S. Food and Drug Administration (FDA) in response to the New Dietary Ingredient Notification (NDIN) for the formulations of Anatabloc® and CigRx® submitted by the Company in June 2014. The letter indicated that the FDA considers anatabine citrate, a principal ingredient in these products, to be a drug, because anatabine citrate is intended to provide anti-inflammatory support, and is the subject of a previously filed Investigational New Drug Application (INDA).
Firm halting sales of dietary supplement Anatabloc
By MICHAEL FELBERBAUM - AP - Mon Aug 11, 5:45PM CDT
RICHMOND, Va. (AP) — The dietary supplement maker at the center of a federal trial of former Virginia Gov. Bob McDonnell and his wife is halting sales of its product called Anatabloc.
Rock Creek Pharmaceuticals Reports Second Quarter and Announces Clinical Update
PR Newswire - Mon Aug 11, 3:20PM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today that it filed with the Securities Exchange Commission its Form 10-Q for the second quarter ended June 30, 2014. The company has also announced a clinical and regulatory update.
Rock Creek Pharmaceuticals Expands The Board with the Appointment of Two Independent Directors
PR Newswire - Wed Aug 06, 12:04PM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced that the Company has made two key independent appointments to the Company's Board of Directors with the recent election of Ms. Lee M. Canaan, CFA and Mr. Edward J. McDonnell, MPH. as new directors.
Rock Creek Pharmaceuticals to Present at the Annual BioPharm America International Partnering Conference
PR Newswire - Mon Aug 04, 1:49PM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced that the Company has been selected to present at the Next Generation Track at BioPharm America 2014 in Boston (Sept. 22-24, 2014) at The Boston Marriott Copley Place.
Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs
PR Newswire - Thu Jul 31, 2:31PM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced today that it has initiated the development of its lead molecule, Anatabine Citrate, in Europe; and that it has selected Quotient Clinical, The Translational Pharmaceutics Company, based in the United Kingdom (UK) to run its early development programs.
Consumer Staples Stocks Technical Snapshot -- Procter and Gamble, Clorox, Rock Creek Pharma, Nu Skin Enterprises, and Estee Lauder Cos
PR Newswire - Wed Jul 23, 7:50AM CDT
On Tuesday, July 22, 2014, the NASDAQ Composite ended at 4,456.02, up 0.71%, the Dow Jones Industrial Average finished the day 0.36% higher at 17,113.54, and the S&P 500 closed at 1,983.53, up 0.50%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Consumer Staples Sector Index ended the day at 461.51, down 0.20%, while the index has advanced 3.04% in the previous three months. Investor-Edge has initiated coverage on the following equities: The Procter & Gamble Company (NYSE: PG), The Clorox Company (NYSE: CLX), Rock Creek Pharmaceuticals Inc. (NASDAQ: RCPI), Nu Skin Enterprises Inc. (NYSE: NUS), and The Estee Lauder Companies Inc. (NYSE: EL). Free research on these five companies can be accessed at:
Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application
PR Newswire - Fri Jul 11, 3:30PM CDT
Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI), an emerging biotechnology company, today announced that the Food and Drug Administration ("FDA"
, has notified the Company that the agency will provide comments on RCP's Investigational New Drug ("IND" application before granting the Company permission to start its clinical trial in the US.
Technical Scrutiny on Consumer Staples Stocks -- Research on Diageo, Clorox, Campbell Soup, and Rock Creek Pharma
PR Newswire - Fri Jun 13, 7:20AM CDT
On Thursday, June 12, 2014, the NASDAQ Composite ended at 4,297.63, down 0.79%, the Dow Jones Industrial Average edged 0.65% lower, to finish the day at 16,734.19, and the S&P 500 closed at 1,930.11, down 0.71%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Consumer Staples Sector Index ended the day at 457.51, down 0.85%, while the index has advanced 4.60% in the previous three months. Investor-Edge has initiated coverage on the following equities: Diageo PLC (NYSE: DEO), The Clorox Co. (NYSE: CLX), Campbell Soup Co. (NYSE: CPB) and Rock Creek Pharmaceuticals Inc. (NASDAQ: RCPI). Free technical research on DEO, CLX, CPB and RCPI can be downloaded upon signing up at:
Bankruptcy Filing Fallout Continues For NII Holdings
at The Street - Fri Sep 19, 4:16PM CDT
Corinthian Colleges Inc (NASDAQ:COCO), Rock Creek Pharmaceuticals Inc (NASDAQ:RCPI) and dELiA*s, Inc. (NASDAQ
LIA) are today's top-gaining stocks. The losers are NII Holdings Inc (NASDAQ:NIHD), T... Rite Aid Plunges As Full-Year Outlook Dims
at The Street - Thu Sep 18, 12:04PM CDT
KiOR Inc (NASDAQ:KIOR), NII Holdings Inc (NASDAQ:NIHD) and Rock Creek Pharmaceuticals Inc (NASDAQ:RCPI) are this Thursday's top-gaining billionaire investment picks. On the losing end are Repros ...
Rock Creek Pharmaceuticals Receives New Dietary Ingredient Notification (NDIN) Response
PR Newswire - Fri Sep 12, 7:30AM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today it has received a written response from the U.S. Food and Drug Administration (FDA) in response to the New Dietary Ingredient Notification (NDIN) for the formulations of Anatabloc® and CigRx® submitted by the Company in June 2014. The letter indicated that the FDA considers anatabine citrate, a principal ingredient in these products, to be a drug, because anatabine citrate is intended to provide anti-inflammatory support, and is the subject of a previously filed Investigational New Drug Application (INDA).
Firm halting sales of dietary supplement Anatabloc
By MICHAEL FELBERBAUM - AP - Mon Aug 11, 5:45PM CDT
RICHMOND, Va. (AP) — The dietary supplement maker at the center of a federal trial of former Virginia Gov. Bob McDonnell and his wife is halting sales of its product called Anatabloc.
Rock Creek Pharmaceuticals Reports Second Quarter and Announces Clinical Update
PR Newswire - Mon Aug 11, 3:20PM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today that it filed with the Securities Exchange Commission its Form 10-Q for the second quarter ended June 30, 2014. The company has also announced a clinical and regulatory update.
Rock Creek Pharmaceuticals Expands The Board with the Appointment of Two Independent Directors
PR Newswire - Wed Aug 06, 12:04PM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced that the Company has made two key independent appointments to the Company's Board of Directors with the recent election of Ms. Lee M. Canaan, CFA and Mr. Edward J. McDonnell, MPH. as new directors.
Rock Creek Pharmaceuticals to Present at the Annual BioPharm America International Partnering Conference
PR Newswire - Mon Aug 04, 1:49PM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced that the Company has been selected to present at the Next Generation Track at BioPharm America 2014 in Boston (Sept. 22-24, 2014) at The Boston Marriott Copley Place.
Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs
PR Newswire - Thu Jul 31, 2:31PM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced today that it has initiated the development of its lead molecule, Anatabine Citrate, in Europe; and that it has selected Quotient Clinical, The Translational Pharmaceutics Company, based in the United Kingdom (UK) to run its early development programs.
Consumer Staples Stocks Technical Snapshot -- Procter and Gamble, Clorox, Rock Creek Pharma, Nu Skin Enterprises, and Estee Lauder Cos
PR Newswire - Wed Jul 23, 7:50AM CDT
On Tuesday, July 22, 2014, the NASDAQ Composite ended at 4,456.02, up 0.71%, the Dow Jones Industrial Average finished the day 0.36% higher at 17,113.54, and the S&P 500 closed at 1,983.53, up 0.50%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Consumer Staples Sector Index ended the day at 461.51, down 0.20%, while the index has advanced 3.04% in the previous three months. Investor-Edge has initiated coverage on the following equities: The Procter & Gamble Company (NYSE: PG), The Clorox Company (NYSE: CLX), Rock Creek Pharmaceuticals Inc. (NASDAQ: RCPI), Nu Skin Enterprises Inc. (NYSE: NUS), and The Estee Lauder Companies Inc. (NYSE: EL). Free research on these five companies can be accessed at:
Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application
PR Newswire - Fri Jul 11, 3:30PM CDT
Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI), an emerging biotechnology company, today announced that the Food and Drug Administration ("FDA"
, has notified the Company that the agency will provide comments on RCP's Investigational New Drug ("IND" application before granting the Company permission to start its clinical trial in the US. Technical Scrutiny on Consumer Staples Stocks -- Research on Diageo, Clorox, Campbell Soup, and Rock Creek Pharma
PR Newswire - Fri Jun 13, 7:20AM CDT
On Thursday, June 12, 2014, the NASDAQ Composite ended at 4,297.63, down 0.79%, the Dow Jones Industrial Average edged 0.65% lower, to finish the day at 16,734.19, and the S&P 500 closed at 1,930.11, down 0.71%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Consumer Staples Sector Index ended the day at 457.51, down 0.85%, while the index has advanced 4.60% in the previous three months. Investor-Edge has initiated coverage on the following equities: Diageo PLC (NYSE: DEO), The Clorox Co. (NYSE: CLX), Campbell Soup Co. (NYSE: CPB) and Rock Creek Pharmaceuticals Inc. (NASDAQ: RCPI). Free technical research on DEO, CLX, CPB and RCPI can be downloaded upon signing up at:
